San Jose BioCenter

Meet With... Takeda Research Investment, Inc.
July 21, 2009 | 9:00 am - 4:00 pm | San Jose BioCenter

Speaker
Juan Harrison, Vice President, Takeda Research Investment, Inc.

Takeda Research Investment, Inc. (TRI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC) a world-class pharmaceutical company and the largest in Japan. A wholly-owned subsidiary of Takeda America Holdings, Inc., TRI started operations in 2002. Our aim is to encourage and support therapeutic innovation in biopharmaceutical companies and academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.

At this event companies will hear a presentation by Takeda Research Investment, Inc. to hear what they are looking for in a company. Then the attendees will have a private meeting with Vice President, Juan Harrison. The “Meet with…” Series provides greater access to a pipeline of emerging companies for Foundations, Angels, Investors, Governmental Agencies, Big Pharmas, and others who have partnering and/or financing opportunities. To apply, please send executive summary to events@sjbiocenter.com

Speaker Bio

Juan M.E. Harrison, Vice President, Takeda Research Investment, Inc.
Mr. Harrison joined TRI as Vice President in January 2008. He brings more than 21 years of biopharmaceutical R&D, product licensing, business development and strategy experience. Most recently, Mr. Harrison was a partner with ProPharma Partners International, where he specialized in developing and implementing business and licensing strategy for emerging and established biopharmaceutical companies. Prior to this, he held senior business development positions at XenoPort Inc., PowderJect Inc., Connetics Corporation and Alza Corporation. In addition, Mr. Harrison held product development management and research positions at Alza, where he began his career in 1985. Mr. Harrison received his Bachelor of Sciences in Combined Sciences from Santa Clara University in California, USA. Read more

BioCenter Open House Tour
August 1, 2009 - 2:30 - 3:30 pm
The Open House Tour is an opportunity for anyone interested in the BioCenter to tour the facility and Core labs, to meet the management, and learn more about the BioCenter history and its clients. The tour starts at 2:30 pm and lasts around an hour depending on attendance and how curious you are!
Lauren@sjbiocenter.com to sign up.

BioCenter Annual BBQ
August 27, 2009 - 1:00 - 4:00 pm

BioCenter Open House Tour
September 2, 2009 - 2:30 - 3:30 pm
The Open House Tour is an opportunity for anyone interested in the BioCenter to tour the facility and Core labs, to meet the management, and learn more about the BioCenter history and its clients. The tour starts at 2:30 pm and lasts around an hour depending on attendance and how curious you are!
Lauren@sjbiocenter.com to sign up.

Industry Panel Series
Financial Darwinism: Which Companies are the Fittest - September 22, 2009

Confirmed Speakers:
Peter McWilliams, Principal, Sanderling Ventures
Bob Ward, Principal, Kaiser Permanente Ventures
Anna Williamson, Business Development, Genentech Inc.
Doug Fisher, Principal, InterWest Partners
Facilitator: Scott Iyama, Corporate Attorney, Orrick, Herrington & Sutcliffe LLP

Modern evolution theory suggests only the fittest will survive; in the business world, we know this to be fact. Find out what it takes to prepare your company for survival. Join this panel to hear survival tips from VC investors, and what they look for in a investment.
Read more

Peter McWilliams, Principal, Sanderling Ventures
Peter McWilliams is a Principal with Sanderling Ventures and has more than 15 years experience in biomedical research and management. He works actively with Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Actimis Pharmaceuticals (sold to Boehringer Ingelheim), Trinity Biosystems, Artielle Immunotherapeutics, Harkness Pharmaceuticals, Calcimedica and Cylene Pharmaceuticals. Prior to joining Sanderling, Dr. McWilliams worked at Genentech where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin. Prior to that he was an Associate with Booz.Allen & Hamilton in San Francisco where he focused on projects for major US and International life science companies. Prior to that he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics, where he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange. Dr. McWilliams received an M.B.A. from Columbia Business School, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. and M.A. in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University.

Bob Ward, Principal, Kaiser Permanente Ventures
Bob was instrumental in establishing the Kaiser Permanente Venture Fund in 2000 and is responsible for managing the pipeline of new venture prospects, as well as leading investment evaluations and financing decisions. He is a manager or board observer for several portfolio companies and targets investments in imaging, lab/diagnostics, women's health and related therapeutics/devices. Prior to joining Kaiser Permanente in 1997, Bob pursued a career in banking at Wells Fargo and other financial institutions with responsibilities in treasury operations, performance planning/metrics, incentive compensation and finance training. He holds a MBA in Finance from the University of California at Berkeley and a Bachelor's Degree in Economics from the University of Washington. Bob has completed the executive management leadership program at the University of North Carolina and Venture Capital Institute graduate programs.

Anna Williamson, Business Development, Genentech Inc.
Anna Williamson is a Senior Manager in the Business Development Department at Genentech. Anna's responsibilities include sourcing, evaluating, and in-licensing research technologies and therapeutic products. While at Genentech, Anna has developed strategic collaborations with academic institutions and with companies such as Curis, Sangamo, Abbott and Symphogen. Prior to joining Genentech in 2004, Anna worked at the University of California Office of Technology Transfer where she was responsible for managing and out-licensing a portfolio of life sciences inventions from multiple UC campuses. Anna holds a BA in Natural Sciences and a Ph.D. in Neuroscience from the University of Cambridge, UK, and carried out post-doctoral research at the University of Colorado and the University of California, San Francisco.

Doug Fisher, Principal, InterWest Partners
Dr. Doug Fisher joined InterWest's life sciences team in 2009, focusing on biopharmaceutical and diagnostics investments. Prior to joining InterWest, Dr. Fisher was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. He was involved with several investments, including: Pearl Therapeutics, Access Closure, and GluMetrics. Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area and consulted for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group where he developed product strategies in three new disease areas for Remicade. Dr. Fisher received an A.B. in economics with honors and distinction and a B.S. in biology with distinction from Stanford where he graduated Phi Beta Kappa. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton where he graduated with honors as a Siebel Scholar and Palmer Scholar.

Facilitator: Scott Iyama, Corporate Attorney, Orrick, Herrington & Sutcliffe LLP
Scott Iyama, a corporate associate in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings and technology transactions.

Meet With... Merck & Co., Inc.
September 24, 2009 | 9:00 am - 4:00 pm | San Jose BioCenter

Speakers
James M. Schaeffer, PhD, Executive Director, Licensing And External Research, Merck Research Laboratories, Merck & Co., Inc.
Yael Weiss, MD, PhD, Director, Licensing And External Research, Merck Research Laboratories, Merck & Co., Inc.

The “Meet with…” Series provides greater access to a pipeline of emerging companies for Foundations, Angels, Investors, Governmental Agencies, Big Pharmas, and others who have partnering and/or financing opportunities. Merck is a global research-driven pharmaceutical company dedicated to putting patients first. We discover, develop, manufacture, and market vaccines and medicines to address unmet medical needs, directly and through alliances with our partners. Our mission is to provide people with superior products and services by developing innovations and solutions that improve the quality of life. The focus of research at Merck is on innovation in all areas of drug research and development, working on programs to satisfy unmet medical needs.

At this event companies will hear a presentation by Merck & Co., Inc. to first find out what they are looking for in a company. Then the attendees will have a private meeting with one of the speakers for 20 mins. To apply, please send executive summary to events@sjbiocenter.com

Speaker Bios

James M. Schaeffer, PhD, Executive Director, Licensing And External Research, Merck Research Laboratories, Merck & Co., Inc.
Dr. Jim Schaeffer joined Merck Research Laboratories (MRL) in 1986. During his first 16 years at MRL, he directed research groups focusing primarily on neuroendocrine-related projects. Jim joined the Department of External Scientific Affairs in 2003 with primary responsibility for all neuroscience licensing opportunities and during the next 18 months, he was directly involved in the signing of four major agreements. Jim moved to San Diego in 2004 to assume the role of Merck’s “Science Scout” on the West Coast, with the responsibility to identify new opportunities across all therapeutic areas at all stages of development including enabling technologies. During the past four years, Jim has been directly involved in the execution of 7 major agreements with West Coast based organizations including recent agreements with AmbrX, Marcadia, MediVas, the Gladstone Institute, the University of California in San Francisco and the University of Texas-Southwestern. As of July 2008, Jim is also responsible for Merck's scouting efforts in China.

Yael Weiss, MD, PhD, Director, Licensing And External Research, Merck Research Laboratories, Merck & Co., Inc.
Yael completed her MSc and PhD in molecular genetics at the Weizmann Institute of Science, Rehovot, Israel and obtained her medical degree at Hadassah Medical Center, affiliated with The Hebrew University of Jerusalem, Israel. After practicing medicine for a few years, Yael joined an Israeli venture capital firm as a vice president responsible for analyzing and maintaining deal flow, and then moved on to become a medical and business development director at Genzyme Israel. Yael joined MSD Israel as medical director in the beginning of 2004 and in 2007 she joined Merck's Licensing group in San Francisco as a scientific scout responsible for identification of licensing opportunities emanating from the West Coast. Read more

BioCenter Open House Tour
October 7, 2009 - 2:30 - 3:30 pm
The Opn House Tour is an opportunity for anyone interested in the BioCenter ro roue rhw facility and Core labs, to meet the management, and learn more about the BioCenter history and its clients. The tour starts at 2:30 pm and lasts around an hour depending on attendance and how curious you are!
Lauren@sjbiocenter.com to sign up.

BioCenter Open House Tour
November 4, 2009 - 2:30 - 3:30 pm
The Opn House Tour is an opportunity for anyone interested in the BioCenter ro roue rhw facility and Core labs, to meet the management, and learn more about the BioCenter history and its clients. The tour starts at 2:30 pm and lasts around an hour depending on attendance and how curious you are!
Lauren@sjbiocenter.com to sign up.

BioCenter Open House Tour
December 2, 2009 - 2:30 - 3:30 pm
The Opn House Tour is an opportunity for anyone interested in the BioCenter ro roue rhw facility and Core labs, to meet the management, and learn more about the BioCenter history and its clients. The tour starts at 2:30 pm and lasts around an hour depending on attendance and how curious you are!
Lauren@sjbiocenter.com to sign up.

Industry Panel Series
Trends in Financing December 3, 2009

Steady capital is a must for all companies.�The first step in funding is knowing where to look.�Join experts from the investment world to understand the types of financing that are occurring in your industry today, and what can be expected for 2010. Read more